Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BI 4060107 in Advanced Solid Tumours
NCT07827144Phase 1Recruiting
- Sponsor
- Aimed Bio
- Start
- Oct 2026
- Primary completion
- May 2030
- Countries
- 5
01
Overview
Phase 1, open-label trial of ODS025 in solid tumor (5 cohorts), sponsored by Aimed Bio. Primary endpoint: Dose Limiting Toxicity at 21 days. Started Oct 2026; status: recruiting.
02
Drugs
ODS025
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT07827144.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07827144.